{"product_id":"global-cancer-genome-sequencing-market-growth-status-and-outlook-2023-2029","title":"Global Cancer Genome Sequencing Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Cancer Genome Sequencing Market Growth (Status and Outlook) 2023-2029\u003cbr\u003e\nCancer genome sequencing refers to a method used to identify the complete DNA or RNA sequence of cancer cells based on the sequencing of a single, homogeneous or heterogeneous group of tumor cells.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Cancer Genome Sequencing Industry Forecast” looks at past sales and reviews total world Cancer Genome Sequencing sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Genome Sequencing sales for 2023 through 2029. With Cancer Genome Sequencing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Genome Sequencing industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Cancer Genome Sequencing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Genome Sequencing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Genome Sequencing market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Genome Sequencing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Genome Sequencing.\u003c\/p\u003e\n\n\u003cp\u003eThe global Cancer Genome Sequencing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eIt is a laboratory technique that characterizes DNA or RNA sequences of primary tumor tissue, the tumor micro environment (such as stromal \/ fibroblast cells), adjacent or distal normal tissue, or metastatic tumor sites. This technique generates information related to identification of nucleotide bases (DNA or RNA), mutation status, copy number and sequence variants, as well as structural variations including fusion genes and chromosomal translocations.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Cancer Genome Sequencing market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nSecond Generation\u003cbr\u003e\nThird Generation\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nTreatment\u003cbr\u003e\nResearch\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nAgilent Technologies\u003cbr\u003e\nGE Healthcare Life Sciences\u003cbr\u003e\nJohnson \u0026amp; Johnson\u003cbr\u003e\nLI-COR Biosciences\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nBeckman Coulter\u003cbr\u003e\nBayer\u003cbr\u003e\nHamilton Thorne Biosciences\u003cbr\u003e\nIntegrated DNA Technologies\u003cbr\u003e\nMicrochip Biotechnologies\u003cbr\u003e\nMyriad Genetics\u003cbr\u003e\nCommonwealth Biotechnologies\u003cbr\u003e\nZS Genetics\u003cbr\u003e\nPacific Biosciences\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"February, 2023 \/ 104 Pages \/ MCW16227494","offer_id":47645964337458,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-cancer-genome-sequencing-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}